Catalog No.
Product Name
Application
Product Information
Citations
-
Spns2 Inhibitor
SLF1081851 is a selective inhibitor of Spns2, effectively inhibiting sphingosine-1-phosphate (S1P) release with an IC50 of 1.93 μM. This compound is crucial for studying developmental processes and immune responses, making it a valuable tool in research focused on modulating these biological pathways. Its ability to target Spns2 provides insight into the mechanisms regulating S1P availability and its subsequent effects on cell signaling and function. -
Spns2 Inhibitor
SLF80821178 is a potent inhibitor of the Sphingosine-1-Phosphate Transporter (Spns2), exhibiting an IC50 of 51 nM for the inhibition of S1P release in HeLa cells. This orally active compound demonstrates a half-life of 2.4 hours in mouse models. Research applications include the investigation of sphingosine metabolism and transport in cellular signaling pathways. -
LPL Receptor Inhibitor
S1PR1 modulator 1 is a selective inhibitor of the S1PR1 receptor, demonstrating a pIC50 of 7.6 and exhibiting greater than 40-fold selectivity over S1PR2 and over 80-fold selectivity over S1PR3 and S1PR4. This compound is valuable for investigating S1PR1-mediated signaling pathways and its role in various biological processes, including immune response regulation and cardiovascular function. Its specificity makes it an important tool for research applications focused on the modulation of S1P receptor activity in disease models. -
Autotaxin Inhibitor
CRT0273750 is an inhibitor of autotaxin (ATX), which plays a crucial role in the modulation of lysophosphatidic acid (LPA) levels, exhibiting an IC50 of 0.014 μM. This compound is valuable in the study of ATX/LPA-dependent cancer models, contributing to research on tumor progression and metastasis. Its specificity for ATX provides a useful tool for elucidating the underlying mechanisms of LPA-mediated signaling pathways in various biological contexts. -
LPL Receptor Agonist
Ceralifimod is a potent and selective agonist for the sphingosine 1-phosphate receptors 1 and 5, exhibiting effective EC50 values of 27.3 pM and 334 pM for human S1P receptor 1 and 5, respectively. This compound is primarily utilized in research applications investigating immune modulation and cardiovascular disease. Its targeted mechanism provides valuable insights into receptor signaling pathways relevant to inflammation and tissue homeostasis. -
Spns2 Inhibitor
SLB1122168 is a selective inhibitor of Spns2 that significantly impairs the release of sphingosine-1-phosphate (S1P) with an IC50 of 94 nM. This compound is useful for investigating the role of S1P in various biological processes, including immune response and cardiovascular regulation. Its application in research can help elucidate the mechanisms underlying Spns2 activity and S1P signaling pathways. -
LPL Receptor Agonist
S1P1 Agonist 1 targets the sphingosine-1-phosphate receptor 1 (S1P1) as an agonist, exerting significant immunomodulatory effects. This compound plays a crucial role in modulating immune responses and inflammation, making it valuable for research in immunology and related fields. S1P1 Agonist 1 is instrumental in studies exploring the therapeutic potential of S1P1 activation in various diseases. -
LPL Receptor Agonist
(S)-FTY720-phosphonate is a selective agonist of the S1P receptor 1 (S1PR1). This compound is primarily employed in research related to acute inflammatory diseases, including but not limited to acute lung injury. By activating S1PR1, (S)-FTY720-phosphonate may facilitate studies on its role in immune response modulation and tissue repair mechanisms. -
Sphingosine-1-phosphate Lyase Inhibitor
S1PL-IN-1 is a selective sphingosine-1-phosphate lyase inhibitor with an IC50 of 210 nM. This compound exhibits potential in modulating S1P signaling pathways and may serve as a Smoothened receptor antagonist with an IC50 of 440 nM. S1PL-IN-1 is primarily utilized in the study of experimental autoimmune encephalomyelitis and related neurological disorders. Its capacity to influence sphingolipid metabolism makes it a valuable tool for research into neuroinflammatory conditions. -
Lp(a) Antagonist
Lp(a)-IN-8 is a selective antagonist of lipoprotein(a) [Lp(a)], a recognized causal risk factor for atherosclerotic cardiovascular disease (ASCVD). This compound effectively inhibits Lp(a) accumulation, offering potential for reducing cardiovascular risk. Research applications include investigations into ASCVD mechanisms and therapeutic strategies targeting Lp(a) modulation. -
Spns2 Inhibitor
SLF1081851 TFA is a selective inhibitor of Spns2, effectively inhibiting sphingosine-1-phosphate (S1P) release with an IC50 of 1.93 μM. This compound is instrumental in studies related to developmental biology and immune regulation. Its ability to modulate S1P levels makes it a valuable tool for investigating pathways involved in immune responses and developmental processes. -
LPL Receptor Modulator
S1P1 agonist 4 is a potent LPL receptor modulator that exhibits high efficacy with an EC50 of less than 0.05 mg/kg. This compound is characterized by a favorable human half-life, approximately 5 days, making it an ideal candidate for studies involving lipid metabolism and cardiovascular disease research. Its ability to selectively activate S1P1 receptors positions it as a valuable tool for exploring therapeutic strategies in metabolic disorders. -
Lp(a) Antagonist
LPA2 antagonist 6 is a potent antagonist targeting lipoprotein(a) [Lp(a)]. It effectively inhibits Lp(a) formation with an IC50 value of 2.33 nM. This compound is instrumental in cardiovascular disease research, allowing for deeper exploration into the mechanisms of lipoprotein metabolism and its role in associated pathologies. -
LPL Receptor Agonist
GSK2018682 hydrochloride is a specific agonist for the sphingosine-1-phosphate receptors S1P1 and S1P5, exhibiting pEC50 values of 7.7 and 7.2, respectively. It shows no agonist activity toward the S1P2, S1P3, or S1P4 receptors. This compound is primarily utilized in research investigating multiple sclerosis and related neurological disorders, offering insights into the modulation of immune responses and vascular integrity. -
LPL Receptor Modulator
GSK 1842799 TFA is a selective modulator of the S1P1 receptor, primarily developed for the treatment of multiple sclerosis (MS). The phosphorylated derivative, GSK1842799-P, demonstrates subnanomolar agonist activity for S1P1, with over 1000-fold selectivity against S1P3. This compound exhibits favorable pharmacokinetics, including good oral bioavailability and rapid in vivo conversion, leading to significant lymphocyte count reduction at a dose of 0.1 mg/kg. In preclinical models, it showcased comparable efficacy to FTY720, supporting its potential utility in MS research and other immune-related conditions. -
LPL Receptor Agonist
CS-0777-P is a potent and selective agonist of the sphingosine 1-phosphate receptor 1 (S1P1). It displays approximately 320-fold higher activity for human S1P1 compared to S1P3, with an EC50 of 1.1 nM. Biological studies indicate its capability to significantly reduce peripheral blood lymphocyte counts and exert immunosuppressive effects in experimental autoimmune encephalomyelitis models in rats. Pharmacokinetic analysis reveals swift lymphocyte count reductions after oral administration, highlighting CS-0777-P's potential as a therapeutic candidate for multiple sclerosis, currently under clinical investigation. -
R-Isomer of FTY 720P
(R)-FTY 720P is the R-isomer of FTY 720P, primarily targeting sphingosine-1-phosphate receptors S1P1, S1P3, S1P4, and S1P5. It exhibits reduced binding affinities compared to its S-isomer counterpart. This compound is utilized in research applications focused on immune modulation and neuroprotection, contributing to studies involving multiple sclerosis and other autoimmune conditions. -
LPL Receptor Agonist
AUY 954 hydrochloride is a potent and selective agonist of the sphingosine-1-phosphate (S1P(1)) receptor, exhibiting significant immunomodulatory properties. It induces a notable and reversible decrease in circulating lymphocytes following oral administration. In preclinical studies, AUY 954 hydrochloride has shown efficacy in prolonging cardiac allograft survival in conjunction with RAD001, as well as effectively preventing experimental autoimmune neuritis in rat models. This compound holds promising therapeutic potential for various autoimmune conditions. -
LPL Receptor Agonist
NSC12404 is a selective agonist for the lysophosphatidic acid receptor 2 (LPA2). This compound exhibits weak but specific activity, making it a valuable tool for studying LPA2 receptor signaling pathways. Its applications in research include investigating the role of LPA2 in cellular processes such as proliferation, migration, and differentiation. -
Spns2 Inhibitor
SLF80821178 hydrochloride is a selective inhibitor of the sphingosine-1-phosphate transporter (Spns2), effectively reducing sphingosine-1-phosphate (S1P) release in HeLa cells with an IC50 value of 51 nM. This compound demonstrates the capability to decrease circulating lymphocyte levels in mice without altering plasma S1P concentrations, making it a valuable tool for studying immune response and signaling pathways. Research applications include investigations into lymphocyte trafficking and potential therapeutic strategies targeting sphingosine metabolism. -
Spns2 Inhibitor
SLF1081851 hydrochloride is a potent inhibitor of Spns2, effectively suppressing sphingosine-1-phosphate (S1P) release with an IC50 of 1.93 μM. This compound is significant for research into immune system development and related biological processes. It serves as a valuable tool for investigating the role of S1P in various cellular functions and pathological conditions. -
SPL Inhibitor
SPL-IN-1 is a selective sphingosine-1-phosphate lyase inhibitor that targets the SPL enzyme. It has demonstrated significant biological activity in modulating sphingolipid metabolism and influencing cellular signaling pathways. This compound is valuable for research applications involving inflammation, cancer progression, and other diseases associated with sphingosine-1-phosphate signaling dysregulation. -
LPL Receptor Modulator
BMS-986104 is a selective modulator of the S1P1 receptor, exhibiting significant biological activity in promoting remyelination. It demonstrates efficacy in a mouse model of experimental autoimmune encephalomyelitis (EAE), showing comparable results to established agents. Mechanistically, BMS-986104 effectively facilitates remyelination in a three-dimensional brain cell culture assay involving lysophosphatidylcholine-induced demyelination, making it a valuable tool for research on neurodegenerative diseases and myelin repair mechanisms. -
Sphingosine-1-Phosphate Receptor Agonist
Zectivimod is a sphingosine-1-phosphate receptor agonist that plays a crucial role in modulating immune responses. It exhibits significant biological activity in the context of autoimmune diseases, chronic inflammatory conditions, and immunoregulation disorders. This compound is valuable for research aimed at understanding the underlying mechanisms of immune system modulation and the development of therapeutic strategies. -
Sphingosine 1-phosphate Receptor Modulator
CS-0777 is a selective sphingosine 1-phosphate receptor-1 modulator that exhibits oral bioavailability. This compound is primarily utilized in research focused on autoimmune diseases, where it influences immune cell trafficking and potentially alters disease progression. Its mechanism of action offers valuable insights into the therapeutic targeting of sphingosine pathways in various pathological conditions. -
Drug Isomer
(Rac)-1-Oleoyl lysophosphatidic acid is an isomer of 1-Oleoyl lysophosphatidic acid that acts as a potent bioactive lipid. This compound primarily targets the lysophosphatidic acid (LPA) receptors, modulating various cellular responses associated with cell proliferation, migration, and survival. Its application in research includes studies focused on cancer biology, wound healing, and neurobiology, contributing to a better understanding of LPA signaling pathways and their role in disease processes. -
LPL Receptor Antagonist
S1P2 antagonist 1 is a potent oral antagonist of the sphingosine-1-phosphate receptor 2 (S1P2). It demonstrates significant biological activity in inhibiting pathways associated with fibrotic diseases. This compound is suitable for research applications exploring the modulation of fibrogenesis and related pathological conditions. -
SPNS2 Inhibitor
Spns2-IN-3 is a selective SPNS2 inhibitor that targets sphingolipid metabolism. This compound exhibits significant biological activity in modulating sphingolipid pathways, making it crucial for research applications involving cellular signaling and lipid biology. Its unique structure may facilitate the development of drug carriers, enhancing the delivery and penetration of therapeutic molecules across biological membranes, particularly in dermatological settings. -
S1P1 antagonist
(R)-VPC44116 is a selective antagonist of the sphingosine-1-phosphate receptor 1 (S1P1). This compound is primarily utilized in lipid signaling research and plays a crucial role in studying immune response, cell migration, and vascular development. Its ability to modulate S1P1 activity makes it valuable for investigating various pathophysiological conditions, including autoimmune diseases and cardiovascular disorders. -
Phospholipid
1-Arachidonoyl-2-hydroxy-sn-glycero-3-PA is a phospholipid that features arachidonic acid at the sn-1 position and serves as a precursor to 1-arachidonoyl glycerol. This compound exhibits potent binding to the LPA2/EDG4 receptor, with an EC50 value of approximately 10 nM. Its biological activity includes the inhibition of TNF-α and IL-6 secretion in wild-type dendritic cells activated by LPS, as well as the reduction of HT-29 human colon carcinoma cell differentiation into goblet cells upon sodium butyrate treatment. This makes it a valuable tool for studying inflammation and cancer biology. -
SPC Receptor Antagonist
KRO-105714 is a selective antagonist of the sphingosine phosphocholine receptor (SPC Receptor) and the sphingosine-1-phosphate receptor 1 (S1P1 Receptor), with an IC50 of 79.2 nM. This compound effectively inhibits SPC-induced cell proliferation in NIH3T3 cells (IC50 = 5.6 nM), as well as SPC-induced cell migration (IC50 = 0.59 μM) and tube formation in human umbilical vein endothelial cells (HUVECs). Additionally, KRO-105714 suppresses the generation of pro-inflammatory cytokines IL-4 and IL-5, demonstrating its potential for use in anti-inflammatory research, particularly in mouse models of atopic dermatitis. -
S1PR3 antagonist
VPC 01091 is a selective antagonist of the sphingosine-1-phosphate receptor 3 (S1PR3). This compound effectively inhibits S1PR3-mediated signaling pathways, which are implicated in various physiological processes including immune regulation and vascular dynamics. VPC 01091 serves as a valuable tool for research applications aimed at exploring the role of S1PR3 in pathophysiology and therapeutic interventions. -
Sphingosine-1-phosphate Receptor 1 Agonist
AUY954 is a selective agonist of the sphingosine-1-phosphate receptor 1, exhibiting an EC50 of 1.2 nM for the human S1P1 receptor. This compound demonstrates significant biological activity in modulating immune responses and is primarily utilized in research focused on experimental autoimmune neuritis. AUY954's selective action makes it a valuable tool for studying the role of sphingosine-1-phosphate signaling in various autoimmune conditions. -
LPL Receptor Modulator
S1PR1-MO-1 is a modulator of the sphingosine-1-phosphate receptor (S1PR1) that plays a critical role in various cellular processes. It exhibits significant biological activity in regulating inflammatory responses and hyperproliferative conditions. This reagent is primarily utilized in research focused on understanding and developing therapeutic strategies for inflammatory diseases and related disorders.
